Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | - USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 124.15 Thousand USD | -26.45% |
| 2008 | 168.8 Thousand USD | 311.51% |
| 2007 | 41.02 Thousand USD | -51.75% |
| 2006 | 85.02 Thousand USD | 304.86% |
| 2005 | 21 Thousand USD | 425.15% |
| 2004 | 3998.85 USD | -99.06% |
| 2003 | 425.7 Thousand USD | 5241.39% |
| 2002 | 7970.00 USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 1.17 Million USD | 23.84% |
| 1999 | 946.37 Thousand USD | 248.86% |
| 1998 | 271.28 Thousand USD | 97.57% |
| 1997 | 137.3 Thousand USD | 89.24% |
| 1996 | 72.55 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 FY | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 100.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q1 | 2854.15 USD | -96.18% |
| 2010 Q2 | -474.84 USD | -116.64% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | 124.15 Thousand USD | -26.45% |
| 2009 Q4 | 74.69 Thousand USD | 66.95% |
| 2009 Q3 | 44.73 Thousand USD | -47.56% |
| 2009 Q2 | 85.31 Thousand USD | 69.23% |
| 2009 Q1 | 50.41 Thousand USD | 63.06% |
| 2008 Q1 | 2006.94 USD | 100.59% |
| 2008 Q2 | 11.92 Thousand USD | 494.39% |
| 2008 FY | 168.8 Thousand USD | 311.51% |
| 2008 Q3 | - USD | -100.0% |
| 2008 Q4 | 30.91 Thousand USD | 0.0% |
| 2007 Q1 | 26.99 Thousand USD | 58.75% |
| 2007 Q4 | 1000.50 USD | -95.83% |
| 2007 Q3 | 23.96 Thousand USD | -36.97% |
| 2007 Q2 | 38.02 Thousand USD | 40.86% |
| 2007 FY | 41.02 Thousand USD | -51.75% |
| 2006 Q1 | 2995.12 USD | -24.9% |
| 2006 FY | 85.02 Thousand USD | 304.86% |
| 2006 Q4 | 17 Thousand USD | 467.21% |
| 2006 Q3 | 2998.01 USD | -75.05% |
| 2006 Q2 | 12.01 Thousand USD | 301.12% |
| 2005 Q2 | 0.89 USD | -99.96% |
| 2005 Q1 | 1998.57 USD | 0.0% |
| 2005 Q4 | 3988.18 USD | 299.07% |
| 2005 Q3 | 999.37 USD | 111586.37% |
| 2005 FY | 21 Thousand USD | 425.15% |
| 2004 Q2 | -8191.88 USD | 0.0% |
| 2004 Q4 | - USD | -100.0% |
| 2004 Q3 | 1998.20 USD | 124.39% |
| 2004 Q1 | - USD | -100.0% |
| 2004 FY | 3998.85 USD | -99.06% |
| 2003 Q3 | 21.03 Thousand USD | 163.88% |
| 2003 Q4 | 423.11 Thousand USD | 1911.88% |
| 2003 Q2 | 7970.00 USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | 425.7 Thousand USD | 5241.39% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | 7970.00 USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | -100.0% |
| 2001 FY | - USD | -100.0% |
| 2001 Q3 | 1000.21 USD | -99.65% |
| 2001 Q2 | 283 Thousand USD | -1.17% |
| 2001 Q1 | 286.35 Thousand USD | -10.28% |
| 2000 Q1 | 344.57 Thousand USD | 153.7% |
| 2000 Q3 | 297.38 Thousand USD | -35.91% |
| 2000 FY | 1.17 Million USD | 23.84% |
| 2000 Q2 | 463.96 Thousand USD | 34.65% |
| 2000 Q4 | 319.16 Thousand USD | 7.32% |
| 1999 Q2 | 138.69 Thousand USD | 109.23% |
| 1999 Q1 | 66.29 Thousand USD | 1.82% |
| 1999 Q4 | 135.81 Thousand USD | 1.49% |
| 1999 FY | 946.37 Thousand USD | 248.86% |
| 1999 Q3 | 133.81 Thousand USD | -3.52% |
| 1998 Q1 | 70.26 Thousand USD | -0.01% |
| 1998 Q2 | -1611.17 USD | -102.29% |
| 1998 Q4 | 65.1 Thousand USD | 2.89% |
| 1998 Q3 | 63.27 Thousand USD | 4027.28% |
| 1998 FY | 271.28 Thousand USD | 97.57% |
| 1997 Q4 | 70.27 Thousand USD | -2.39% |
| 1997 Q3 | 71.99 Thousand USD | 0.0% |
| 1997 FY | 137.3 Thousand USD | 89.24% |
| 1996 FY | 72.55 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Appili Therapeutics Inc. | 813.74 Thousand CAD | 100.0% |
| Eupraxia Pharmaceuticals Inc. | -209.91 Thousand CAD | 100.0% |
| Helix BioPharma Corp. | -14 Thousand CAD | 100.0% |
| Microbix Biosystems Inc. | 7.48 Million CAD | 100.0% |
| Medicenna Therapeutics Corp. | -5000.00 CAD | 100.0% |
| Satellos Bioscience Inc. | -8.81 Million CAD | 100.0% |
| Oncolytics Biotech Inc. | -403 Thousand CAD | 100.0% |
| Sernova Corp. | -445.55 Thousand CAD | 100.0% |